Alpha Tau Medical Ltd
Company Profile
Business description
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
Contact
Kiryat HaMada Street 5
Jerusalem9777605
ISRT: +972 35774115
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
121
Stocks News & Analysis
stocks
Undervalued ASX share retains wide moat rating despite regulatory pressures
stocks
Our top ASX picks in every sector
stocks
Tesla: Shares fall as deliveries come in below consensus
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,165.70 | 2.00 | 0.02% |
| CAC 40 | 8,272.15 | 363.41 | 4.60% |
| DAX 40 | 24,017.31 | 1,095.72 | 4.78% |
| Dow JONES (US) | 47,912.97 | 1,328.51 | 2.85% |
| FTSE 100 | 10,620.36 | 271.57 | 2.62% |
| HKSE | 25,893.02 | 776.49 | 3.09% |
| NASDAQ | 22,687.83 | 669.98 | 3.04% |
| Nikkei 225 | 56,308.42 | 2,878.86 | 5.39% |
| NZX 50 Index | 13,253.94 | 184.28 | 1.41% |
| S&P 500 | 6,776.33 | 159.48 | 2.41% |
| S&P/ASX 200 | 8,951.80 | 21.00 | -0.23% |
| SSE Composite Index | 3,995.00 | 104.83 | 2.69% |